← Back to Search

Monoclonal Antibodies

Dupilumab for Prurigo Nodularis

Phase 3
Recruiting
Research Sponsored by Sanofi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be ≥6 months to <18 years of age, at the time of signing the informed consent
Participants must have an average worst itch score of ≥7 in the 7 days prior to Day 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up date of signed icf (2-4 weeks before day 1) to week 40
Awards & highlights

Study Summary

This trial is a Phase 3 study that will look at how the body processes a drug and its safety. It will involve multiple medical centers and will be open-label. Participants will go through three periods

Who is the study for?
This clinical trial is for children and teenagers from 6 months to under 18 years old with Prurigo Nodularis, a skin condition causing itchy lumps. They must have been diagnosed at least 3 months prior, have an itch intensity score of ≥7, and lesions on multiple body areas. Participants need to be able to use an e-Diary daily.Check my eligibility
What is being tested?
The study tests Dupilumab's effects on young patients with Prurigo Nodularis over approximately one year. It includes a screening period, a treatment phase lasting six months where the drug is given, followed by four months of observation without treatment.See study design
What are the potential side effects?
Dupilumab may cause side effects such as injection site reactions (redness or swelling), eye irritation or inflammation, cold sores in your mouth or throat area, and allergic reactions that can include rash or hives.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 6 months and 18 years old.
Select...
My worst itch score has been 7 or more in the past week.
Select...
I have been diagnosed with prurigo nodularis for over 3 months, with at least 6 itchy bumps on more than one area of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~date of signed icf (2-4 weeks before day 1) to week 40
This trial's timeline: 3 weeks for screening, Varies for treatment, and date of signed icf (2-4 weeks before day 1) to week 40 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentration of dupilumab in serum
Secondary outcome measures
Incidence of anti-drug antibodies (ADA) to dupilumab over time
Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)

Side effects data

From 2021 Phase 4 trial • 188 Patients • NCT04033367
9%
Conjunctivitis
7%
Headache
3%
Dermatitis Atopic
2%
Nasopharyngitis
1%
Accidental Overdose
1%
Drug Hypersensitivity
1%
Polyarthritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
DB Period: Placebo
DB Period: Dupilumab
OLE Period: Dupilumab/Dupilumab
OLE Period: Placebo/Dupilumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: DupilumabExperimental Treatment1 Intervention
Administered subcutaneously (SC) based on weight and age
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab
2017
Completed Phase 4
~12230

Find a Location

Who is running the clinical trial?

SanofiLead Sponsor
2,170 Previous Clinical Trials
3,516,562 Total Patients Enrolled
2 Trials studying Prurigo Nodularis
700 Patients Enrolled for Prurigo Nodularis
Regeneron PharmaceuticalsIndustry Sponsor
628 Previous Clinical Trials
382,224 Total Patients Enrolled
1 Trials studying Prurigo Nodularis
550 Patients Enrolled for Prurigo Nodularis
~12 spots leftby Oct 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top